Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (785)	3/18/1998 5:22:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1826

It's interesting to compare the results for the HT-29 human colon xenograft for MGI-114 with ITN with those of another abstract being presented. First, for MGI-114/ITN in HT-29 (doesn't say that the mice were nude, but I assume so): When MGI 114 (3.5 mg/kg) was combined with ITN, there were 3 complete responses. The remaining animals (7/9, ITN-50; 8/9, ITN-100) had mean tumor shrinkage of > 75%. When MGI 114 (3.5 mg/kg) was combined with 5-FU there were 5/9 (5-FU-100) animals with mean tumor shrinkage of 58% and no complete responses. Compare this with the following extract: #3586 Multiple courses of CPT-11 and 5FU combination in HT-29 nude mice xenografts; molecular analysis of tumoral relapse. S. Guichard, I. Hennebelle, P. Canal. Institut Claudius Regaud, Toulouse, France. CPT-11 and 5FU are drugs active in metastatic colorectal cancer. In nude mice bearing HT-29 xenografts, we demonstrated the superiority of sequential CPT-11/5FU combination (Int Journal Cancer, in press). Here we investigated the efficacy of three repetitive courses of CPT-11/5FU chemotherapy and the evolution of cellular targets : thymidylate synthase (TS) and topoisomerase I (Topo I) during treatment. Mice were treated with daily sequential (a delay of 6 hours) administration of 20 mg/kg CPT-11 and 5FU for 5 days and three courses separated by a one week interval. The results of the ratio between the volume at the day 35 and the initial volume are : >5, 4.9 ñ 1.4, 2.4 ñ 0.9 and 2.8 ñ 1.3 for 5FU, CPT-11, CPT-11 then 5FU (CF) and 5FU then CPT-11 (FC) lots, respectively. Tumor growth rate increased along the three courses, demonstrating a relapse. ... ---------------------- So _if_ these studies are comparable, we get complete responses or substantial tumor shrinkage for MGI-114/ITN vs. still pretty rapid tumor growth for the other new combination. Comments from someone who (unlike me!) actually knows something about this stuff would be appreciated. Peter (wearing his amateur oncologist hat)